FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Journal of virology2005; 79(14); 8793-8801; doi: 10.1128/JVI.79.14.8793-8801.2005

Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production.

Abstract: We have previously reported that serial truncation of the Gag p9 protein of equine infectious anemia virus (EIAV) revealed a progressive loss in replication phenotypes in transfected cells, such that a proviral mutant (E32) expressing the N-terminal 31 amino acids of p9 produced infectious virus particles similarly to parental provirus, while a proviral mutant (K30) with two fewer amino acids produced replication-defective virus particles, despite containing apparently normal levels of processed Gag and Pol proteins (C. Chen, F. Li, and R. C. Montelaro, J. Virol. 75:9762-9760, 2001). Based on these observations, we sought in the current study to identify the precise defect in K30 virion infection of permissive equine dermal (ED) cells. The results of these experiments clearly demonstrated that K30 virions entered target ED cells and produced early (minus-strand strong-stop) and late (Gag) viral DNA products as efficiently as did the replication-competent E32 mutant and parental EIAV(UK) viruses. However, in contrast to the replication-competent E32 mutant and parental viruses, infection with K30 mutant virus failed to produce detectable two-long-terminal-repeat DNA circles, stable integrated provirus, virus-specific Gag mRNA expression, or intracellular viral protein expression. Taken together, these data demonstrate that the K30 mutant is defective in the ability to produce sufficient nuclear viral DNA to establish a productive infection in ED cells. Thus, these observations indicate for the first time that the EIAV Gag p9 protein performs a critical role in viral DNA production and processing to provirus during EIAV infection, in addition to its previously defined role in viral budding mediated by the p9 L domain.
Get Full Text
Publication Date: 2005-07-05 PubMed ID: 15994773PubMed Central: PMC1168773DOI: 10.1128/JVI.79.14.8793-8801.2005Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article focuses on the function of the Gag p9 protein of the equine infectious anemia virus (EIAV), particularly in the early stages of virus infection and provirus production. The researchers discovered that a specific strain of the virus (K30) is unable to effectively produce nuclear viral DNA, thereby inhibiting its ability to establish a productive infection in equine dermal cells.

Objective

The study centered on understanding how the truncation and absence of certain amino acids in the EIAV Gag p9 protein impacted the virus’ ability to infect cells and reproduce. Key results showed that a specific proviral mutant (K30) failed to produce two-long-terminal-repeat DNA circles and stably integrate its provirus.

Methodology

  • The researchers made use of serial truncation of the EIAV Gag p9 protein, creating mutant strains with varying lengths of this protein.
  • They conducted their study with two proviral mutants— E32 and K30, each having different lengths of the p9 protein.
  • The infection and replication ability of these mutants were observed in experiments on equine dermal cells.

Results

  • The research found that the K30 mutant entered the target cells and created early and late viral DNA products as effectively as the E32 mutant and the parental EIAV.
  • However, unlike the latter, the K30 strain couldn’t produce the necessary DNA circles or establish a significant provirus, thereby inhibiting the expression of virus-specific Gag mRNA and intracellular viral protein.
  • These findings led to the conclusion that the K30 mutant lacked the ability to generate enough nuclear viral DNA to cause a productive infection in equine dermal cells.

Significance

  • The study offers key insights into the role of the EIAV Gag p9 protein in the virus’ lifecycle, suggesting it plays a critical role in viral DNA production, processing to provirus during EIAV infection, in addition to its previously defined role in viral budding.
  • This understanding can prove beneficial in the development of treatments against EIAV, as the disruption of the Gag p9 protein could potentially halt the spread of the virus within hosts.

Cite This Article

APA
Jin S, Chen C, Montelaro RC. (2005). Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production. J Virol, 79(14), 8793-8801. https://doi.org/10.1128/JVI.79.14.8793-8801.2005

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 79
Issue: 14
Pages: 8793-8801

Researcher Affiliations

Jin, Sha
  • Department of Molecular Genetics and Biochemistry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Chen, Chaoping
    Montelaro, Ronald C

      MeSH Terms

      • Active Transport, Cell Nucleus
      • Animals
      • COS Cells
      • DNA, Viral / biosynthesis
      • Gene Products, gag / physiology
      • Horses
      • Infectious Anemia Virus, Equine / physiology
      • Proviruses / physiology
      • Transcription, Genetic
      • Viral Proteins / biosynthesis
      • Virus Integration
      • Virus Replication

      Grant Funding

      • R01 CA049296 / NCI NIH HHS
      • R01 CA49296 / NCI NIH HHS

      References

      This article includes 66 references
      1. Adamson CS, Jones IM. The molecular basis of HIV capsid assembly--five years of progress.. Rev Med Virol 2004 Mar-Apr;14(2):107-21.
        pubmed: 15027003doi: 10.1002/rmv.418google scholar: lookup
      2. Allain B, Lapadat-Tapolsky M, Berlioz C, Darlix JL. Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome.. EMBO J 1994 Feb 15;13(4):973-81.
        pmc: PMC394899pubmed: 7509280doi: 10.1002/j.1460-2075.1994.tb06342.xgoogle scholar: lookup
      3. Ansari-Lari MA, Donehower LA, Gibbs RA. Analysis of human immunodeficiency virus type 1 integrase mutants.. Virology 1995 Nov 10;213(2):680.
        pubmed: 7491794
      4. Bouyac-Bertoia M, Dvorin JD, Fouchier RA, Jenkins Y, Meyer BE, Wu LI, Emerman M, Malim MH. HIV-1 infection requires a functional integrase NLS.. Mol Cell 2001 May;7(5):1025-35.
        pubmed: 11389849doi: 10.1016/s1097-2765(01)00240-4google scholar: lookup
      5. Bukrinsky MI, Haffar OK. HIV-1 nuclear import: matrix protein is back on center stage, this time together with Vpr.. Mol Med 1998 Mar;4(3):138-43.
        pmc: PMC2230352pubmed: 9562972
      6. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M. Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.. Proc Natl Acad Sci U S A 1992 Jul 15;89(14):6580-4.
        pmc: PMC49545pubmed: 1631159doi: 10.1073/pnas.89.14.6580google scholar: lookup
      7. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.. Proc Natl Acad Sci U S A 1993 Jul 1;90(13):6125-9.
        pmc: PMC46880pubmed: 7687060doi: 10.1073/pnas.90.13.6125google scholar: lookup
      8. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo.. Nat Med 2001 May;7(5):631-4.
        pubmed: 11329067doi: 10.1038/87979google scholar: lookup
      9. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles.. J Virol 2002 Apr;76(8):3739-47.
        pmc: PMC136088pubmed: 11907213doi: 10.1128/jvi.76.8.3739-3747.2002google scholar: lookup
      10. Cartier C, Sivard P, Tranchat C, Decimo D, Desgranges C, Boyer V. Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection.. J Biol Chem 1999 Jul 2;274(27):19434-40.
        pubmed: 10383459doi: 10.1074/jbc.274.27.19434google scholar: lookup
      11. Chen C, Li F, Montelaro RC. Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.. J Virol 2001 Oct;75(20):9762-70.
        pmc: PMC114548pubmed: 11559809doi: 10.1128/JVI.75.20.9762-9770.2001google scholar: lookup
      12. Chen Y, Balakrishnan M, Roques BP, Bambara RA. Steps of the acceptor invasion mechanism for HIV-1 minus strand strong stop transfer.. J Biol Chem 2003 Oct 3;278(40):38368-75.
        pubmed: 12878597doi: 10.1074/jbc.M305700200google scholar: lookup
      13. Clague MJ, Urbé S. Hrs function: viruses provide the clue.. Trends Cell Biol 2003 Dec;13(12):603-6.
        pubmed: 14624836doi: 10.1016/j.tcb.2003.10.002google scholar: lookup
      14. Cook RF, Cook SJ, Li FL, Montelaro RC, Issel CJ. Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV).. J Virol Methods 2002 Aug;105(1):171-9.
        pubmed: 12176154doi: 10.1016/s0166-0934(02)00101-5google scholar: lookup
      15. Cook RF, Leroux C, Cook SJ, Berger SL, Lichtenstein DL, Ghabrial NN, Montelaro RC, Issel CJ. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus.. J Virol 1998 Feb;72(2):1383-93.
        pmc: PMC124617pubmed: 9445039doi: 10.1128/JVI.72.2.1383-1393.1998google scholar: lookup
      16. Darlix JL, Lapadat-Tapolsky M, de Rocquigny H, Roques BP. First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses.. J Mol Biol 1995 Dec 8;254(4):523-37.
        pubmed: 7500330doi: 10.1006/jmbi.1995.0635google scholar: lookup
      17. Demirov DG, Ono A, Orenstein JM, Freed EO. Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.. Proc Natl Acad Sci U S A 2002 Jan 22;99(2):955-60.
        pmc: PMC117412pubmed: 11805336doi: 10.1073/pnas.032511899google scholar: lookup
      18. Dorfman T, Mammano F, Haseltine WA, Göttlinger HG. Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.. J Virol 1994 Mar;68(3):1689-96.
        pmc: PMC236628pubmed: 8107229doi: 10.1128/JVI.68.3.1689-1696.1994google scholar: lookup
      19. Druillennec S, Dong CZ, Escaich S, Gresh N, Bousseau A, Roques BP, Fournié-Zaluski MC. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.. Proc Natl Acad Sci U S A 1999 Apr 27;96(9):4886-91.
        pmc: PMC21786pubmed: 10220388doi: 10.1073/pnas.96.9.4886google scholar: lookup
      20. Dupont S, Sharova N, DéHoratius C, Virbasius CM, Zhu X, Bukrinskaya AG, Stevenson M, Green MR. A novel nuclear export activity in HIV-1 matrix protein required for viral replication.. Nature 1999 Dec 9;402(6762):681-5.
        pubmed: 10604476doi: 10.1038/45272google scholar: lookup
      21. Engelman A, Englund G, Orenstein JM, Martin MA, Craigie R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication.. J Virol 1995 May;69(5):2729-36.
        pmc: PMC188965pubmed: 7535863doi: 10.1128/JVI.69.5.2729-2736.1995google scholar: lookup
      22. Fitzon T, Leschonsky B, Bieler K, Paulus C, Schröder J, Wolf H, Wagner R. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication.. Virology 2000 Mar 15;268(2):294-307.
        pubmed: 10704338doi: 10.1006/viro.1999.0178google scholar: lookup
      23. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication.. J Virol 2002 Jun;76(11):5667-77.
        pmc: PMC137032pubmed: 11991995doi: 10.1128/jvi.76.11.5667-5677.2002google scholar: lookup
      24. Fouchier RA, Meyer BE, Simon JH, Fischer U, Albright AV, González-Scarano F, Malim MH. Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex.. J Virol 1998 Jul;72(7):6004-13.
        pmc: PMC110405pubmed: 9621063doi: 10.1128/JVI.72.7.6004-6013.1998google scholar: lookup
      25. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions.. Nature 1994 Nov 24;372(6504):359-62.
        pubmed: 7969494doi: 10.1038/372359a0google scholar: lookup
      26. Freed EO, Martin MA. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions.. J Virol 1996 Jan;70(1):341-51.
        pmc: PMC189823pubmed: 8523546doi: 10.1128/JVI.70.1.341-351.1996google scholar: lookup
      27. Goff A, Ehrlich LS, Cohen SN, Carter CA. Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release.. J Virol 2003 Sep;77(17):9173-82.
        pmc: PMC187429pubmed: 12915533doi: 10.1128/jvi.77.17.9173-9182.2003google scholar: lookup
      28. Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H, Pushkarsky T, Nadler SG, Bukrinsky M. Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex.. J Mol Biol 2000 Jun 2;299(2):359-68.
        pubmed: 10860744doi: 10.1006/jmbi.2000.3768google scholar: lookup
      29. Harris JD, Blum H, Scott J, Traynor B, Ventura P, Haase A. Slow virus visna: reproduction in vitro of virus from extrachromosomal DNA.. Proc Natl Acad Sci U S A 1984 Nov;81(22):7212-5.
        pmc: PMC392108pubmed: 6095275doi: 10.1073/pnas.81.22.7212google scholar: lookup
      30. Huang M, Orenstein JM, Martin MA, Freed EO. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.. J Virol 1995 Nov;69(11):6810-8.
        pmc: PMC189593pubmed: 7474093doi: 10.1128/JVI.69.11.6810-6818.1995google scholar: lookup
      31. Jenkins Y, McEntee M, Weis K, Greene WC. Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways.. J Cell Biol 1998 Nov 16;143(4):875-85.
        pmc: PMC2132945pubmed: 9817747doi: 10.1083/jcb.143.4.875google scholar: lookup
      32. Jin S, Issel CJ, Montelaro RC. Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.. Clin Diagn Lab Immunol 2004 Nov;11(6):1120-9.
        pmc: PMC524783pubmed: 15539516doi: 10.1128/CDLI.11.6.1120-1129.2004google scholar: lookup
      33. Kiernan RE, Ono A, Englund G, Freed EO. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.. J Virol 1998 May;72(5):4116-26.
        pmc: PMC109641pubmed: 9557701doi: 10.1128/JVI.72.5.4116-4126.1998google scholar: lookup
      34. Kondo E, Mammano F, Cohen EA, Göttlinger HG. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.. J Virol 1995 May;69(5):2759-64.
        pmc: PMC188969pubmed: 7707498doi: 10.1128/JVI.69.5.2759-2764.1995google scholar: lookup
      35. Lapadat-Tapolsky M, De Rocquigny H, Van Gent D, Roques B, Plasterk R, Darlix JL. Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle.. Nucleic Acids Res 1993 Feb 25;21(4):831-9.
        pmc: PMC309214pubmed: 8383840doi: 10.1093/nar/21.4.831google scholar: lookup
      36. Lapadat-Tapolsky M, Gabus C, Rau M, Darlix JL. Possible roles of HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and in its variability.. J Mol Biol 1997 May 2;268(2):250-60.
        pubmed: 9159468doi: 10.1006/jmbi.1997.0978google scholar: lookup
      37. Lavallée C, Yao XJ, Ladha A, Göttlinger H, Haseltine WA, Cohen EA. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.. J Virol 1994 Mar;68(3):1926-34.
        pmc: PMC236654pubmed: 8107252doi: 10.1128/JVI.68.3.1926-1934.1994google scholar: lookup
      38. Leutenegger CM, von Rechenberg B, Huder JB, Zlinsky K, Mislin C, Akens MK, Auer J, Lutz H. Quantitative real-time PCR for equine cytokine mRNA in nondecalcified bone tissue embedded in methyl methacrylate.. Calcif Tissue Int 1999 Nov;65(5):378-83.
        pubmed: 10541764doi: 10.1007/s002239900717google scholar: lookup
      39. Li F, Chen C, Puffer BA, Montelaro RC. Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication.. J Virol 2002 Feb;76(4):1569-77.
        pmc: PMC135910pubmed: 11799151doi: 10.1128/jvi.76.4.1569-1577.2002google scholar: lookup
      40. Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF. Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin.. J Virol 1999 Apr;73(4):2901-8.
        pmc: PMC104048pubmed: 10074138doi: 10.1128/JVI.73.4.2901-2908.1999google scholar: lookup
      41. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.. Cell 1993 Jun 18;73(6):1067-78.
        pubmed: 8513493doi: 10.1016/0092-8674(93)90637-6google scholar: lookup
      42. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr.. J Virol 1997 Sep;71(9):6339-47.
        pmc: PMC191907pubmed: 9261351doi: 10.1128/JVI.71.9.6339-6347.1997google scholar: lookup
      43. Martin-Serrano J, Perez-Caballero D, Bieniasz PD. Context-dependent effects of L domains and ubiquitination on viral budding.. J Virol 2004 Jun;78(11):5554-63.
        pmc: PMC415830pubmed: 15140952doi: 10.1128/JVI.78.11.5554-5563.2004google scholar: lookup
      44. Montelaro RC, Parekh B, Orrego A, Issel CJ. Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.. J Biol Chem 1984 Aug 25;259(16):10539-44.
        pubmed: 6206055
      45. Morrow CD, Park J, Wakefield JK. Viral gene products and replication of the human immunodeficiency type 1 virus.. Am J Physiol 1994 May;266(5 Pt 1):C1135-56.
        pubmed: 8203479doi: 10.1152/ajpcell.1994.266.5.C1135google scholar: lookup
      46. Nie Z, Bergeron D, Subbramanian RA, Yao XJ, Checroune F, Rougeau N, Cohen EA. The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells.. J Virol 1998 May;72(5):4104-15.
        pmc: PMC109640pubmed: 9557700doi: 10.1128/JVI.72.5.4104-4115.1998google scholar: lookup
      47. Pauza CD, Trivedi P, McKechnie TS, Richman DD, Graziano FM. 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo.. Virology 1994 Dec;205(2):470-8.
        pubmed: 7975248doi: 10.1006/viro.1994.1667google scholar: lookup
      48. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.. J Virol 1993 Dec;67(12):7229-37.
        pmc: PMC238185pubmed: 8230445doi: 10.1128/JVI.67.12.7229-7237.1993google scholar: lookup
      49. Perry ST, Flaherty MT, Kelley MJ, Clabough DL, Tronick SR, Coggins L, Whetter L, Lengel CR, Fuller F. The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.. J Virol 1992 Jul;66(7):4085-97.
        pmc: PMC241211pubmed: 1318398doi: 10.1128/JVI.66.7.4085-4097.1992google scholar: lookup
      50. Petit C, Schwartz O, Mammano F. The karyophilic properties of human immunodeficiency virus type 1 integrase are not required for nuclear import of proviral DNA.. J Virol 2000 Aug;74(15):7119-26.
        pmc: PMC112230pubmed: 10888652doi: 10.1128/jvi.74.15.7119-7126.2000google scholar: lookup
      51. Puffer BA, Parent LJ, Wills JW, Montelaro RC. Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein.. J Virol 1997 Sep;71(9):6541-6.
        pmc: PMC191930pubmed: 9261374doi: 10.1128/JVI.71.9.6541-6546.1997google scholar: lookup
      52. Puffer BA, Watkins SC, Montelaro RC. Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly.. J Virol 1998 Dec;72(12):10218-21.
        pmc: PMC110572pubmed: 9811764doi: 10.1128/JVI.72.12.10218-10221.1998google scholar: lookup
      53. Reicin AS, Ohagen A, Yin L, Hoglund S, Goff SP. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle.. J Virol 1996 Dec;70(12):8645-52.
        pmc: PMC190958pubmed: 8970990doi: 10.1128/JVI.70.12.8645-8652.1996google scholar: lookup
      54. Shank PR, Varmus HE. Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus.. J Virol 1978 Jan;25(1):104-4.
        pmc: PMC353906pubmed: 202729doi: 10.1128/JVI.25.1.104-104.1978google scholar: lookup
      55. Shehu-Xhilaga M, Ablan S, Demirov DG, Chen C, Montelaro RC, Freed EO. Late domain-dependent inhibition of equine infectious anemia virus budding.. J Virol 2004 Jan;78(2):724-32.
        pmc: PMC368837pubmed: 14694104doi: 10.1128/jvi.78.2.724-732.2004google scholar: lookup
      56. Sherman MP, de Noronha CM, Pearce D, Greene WC. Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.. J Virol 2000 Sep;74(17):8159-65.
        pmc: PMC112350pubmed: 10933727doi: 10.1128/jvi.74.17.8159-8165.2000google scholar: lookup
      57. Sherman MP, Greene WC. Slipping through the door: HIV entry into the nucleus.. Microbes Infect 2002 Jan;4(1):67-73.
        pubmed: 11825777doi: 10.1016/s1286-4579(01)01511-8google scholar: lookup
      58. Strack B, Calistri A, Craig S, Popova E, Göttlinger HG. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding.. Cell 2003 Sep 19;114(6):689-99.
        pubmed: 14505569doi: 10.1016/s0092-8674(03)00653-6google scholar: lookup
      59. Tanchou V, Gabus C, Rogemond V, Darlix JL. Formation of stable and functional HIV-1 nucleoprotein complexes in vitro.. J Mol Biol 1995 Oct 6;252(5):563-71.
        pubmed: 7563074doi: 10.1006/jmbi.1995.0520google scholar: lookup
      60. Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, Masuda T. Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells.. J Virol 2000 May;74(10):4795-806.
        pmc: PMC112002pubmed: 10775618doi: 10.1128/jvi.74.10.4795-4806.2000google scholar: lookup
      61. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.. Proc Natl Acad Sci U S A 1994 Jul 19;91(15):6992-6.
        pmc: PMC44324pubmed: 8041734doi: 10.1073/pnas.91.15.6992google scholar: lookup
      62. Werner S, Hindmarsh P, Napirei M, Vogel-Bachmayr K, Wöhrl BM. Subcellular localization and integration activities of rous sarcoma virus reverse transcriptase.. J Virol 2002 Jun;76(12):6205-12.
        pmc: PMC136205pubmed: 12021354doi: 10.1128/jvi.76.12.6205-6212.2002google scholar: lookup
      63. Wiskerchen M, Muesing MA. Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells.. J Virol 1995 Jan;69(1):376-86.
        pmc: PMC188585pubmed: 7983732doi: 10.1128/JVI.69.1.376-386.1995google scholar: lookup
      64. Yamashita M, Emerman M. Capsid is a dominant determinant of retrovirus infectivity in nondividing cells.. J Virol 2004 Jun;78(11):5670-8.
        pmc: PMC415837pubmed: 15140964doi: 10.1128/JVI.78.11.5670-5678.2004google scholar: lookup
      65. Yuan B, Campbell S, Bacharach E, Rein A, Goff SP. Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses.. J Virol 2000 Aug;74(16):7250-60.
        pmc: PMC112246pubmed: 10906179doi: 10.1128/jvi.74.16.7250-7260.2000google scholar: lookup
      66. Yuan B, Li X, Goff SP. Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle.. EMBO J 1999 Sep 1;18(17):4700-10.
        pmc: PMC1171543pubmed: 10469649doi: 10.1093/emboj/18.17.4700google scholar: lookup

      Citations

      This article has been cited 9 times.
      1. Lei H, Jin S, Karlsson E, Schultz-Cherry S, Ye K. Yeast Surface-Displayed H5N1 Avian Influenza Vaccines. J Immunol Res 2016;2016:4131324.
        doi: 10.1155/2016/4131324pubmed: 28078309google scholar: lookup
      2. Wang XF, Lin YZ, Li Q, Liu Q, Zhao WW, Du C, Chen J, Wang X, Zhou JH. Genetic Evolution during the development of an attenuated EIAV vaccine. Retrovirology 2016 Feb 3;13:9.
        doi: 10.1186/s12977-016-0240-6pubmed: 26842878google scholar: lookup
      3. Jin S, Yao H, Weber JL, Melkoumian ZK, Ye K. A synthetic, xeno-free peptide surface for expansion and directed differentiation of human induced pluripotent stem cells. PLoS One 2012;7(11):e50880.
        doi: 10.1371/journal.pone.0050880pubmed: 23226418google scholar: lookup
      4. Jin S, Yao H, Krisanarungson P, Haukas A, Ye K. Porous membrane substrates offer better niches to enhance the Wnt signaling and promote human embryonic stem cell growth and differentiation. Tissue Eng Part A 2012 Jul;18(13-14):1419-30.
        doi: 10.1089/ten.TEA.2011.0474pubmed: 22429220google scholar: lookup
      5. Wang X, Wang S, Lin Y, Jiang C, Ma J, Zhao L, Lv X, Wang F, Shen R, Zhou J. Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus. Virus Genes 2011 Apr;42(2):220-8.
        doi: 10.1007/s11262-010-0563-7pubmed: 21369830google scholar: lookup
      6. Sharma A, Bruns K, Röder R, Henklein P, Votteler J, Wray V, Schubert U. Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein. BMC Struct Biol 2009 Dec 17;9:74.
        doi: 10.1186/1472-6807-9-74pubmed: 20015412google scholar: lookup
      7. Jin S, Zhang B, Weisz OA, Montelaro RC. Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway. J Virol 2005 Dec;79(23):14489-97.
        doi: 10.1128/JVI.79.23.14489-14497.2005pubmed: 16282448google scholar: lookup
      8. Schimmich C, Vabret A, Valle-Casuso JC. Efficacy assessment of antiretroviral drugs against equine infectious anemia virus in vitro. Virus Res 2024 Dec;350:199503.
        doi: 10.1016/j.virusres.2024.199503pubmed: 39613191google scholar: lookup
      9. Zhang B, Jin S, Jin J, Li F, Montelaro RC. A tumor necrosis factor receptor family protein serves as a cellular receptor for the macrophage-tropic equine lentivirus. Proc Natl Acad Sci U S A 2005 Jul 12;102(28):9918-23.
        doi: 10.1073/pnas.0501560102pubmed: 15985554google scholar: lookup
      Subscribe to our newsletter
      Join 99,850 horse owners like you who receive our email updates on horse health and nutrition.